Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on HIV (Feb 2021)

Posted by Matt Breese on Feb 26, 2021

Find me on:

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for HIV treatments shows that under the pharmacy benefit, about 74% of the lives under commercial formularies are covered without utilization management restrictions.

MMIT-Reality Check-HIV-1Q2021Data snapshot as of Q1 2021

Trends: In January 2021, the FDA approved ViiV Healthcare’s Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV-1 infection in adults to replace a current antiretroviral regimen in people who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine.  

To read the full Reality Check on HIV treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing